Treatment of Helicobacter pylori infection of the stomach

Phase 3

• Conditions: helicobacter pylori infection.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20201007048956N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

chronic gastritis with or without healed duodenal or stomach ulcer
H. pylori positive determined by Rapid UreaseTest or Urea Breath Test
treatment-naive patients for eradication of H. pylori infection

Exclusion Criteria

allergy to medications used in this clinical trial
use of PPI, histamine H2-receptor antagonists, antibiotics, bismuth, or probiotics 4 weeks before initiating study
pregnancy or breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Helicobacter pylori infection. Timepoint: 45 days after intervention. Method of measurement: stool antigen test of helicobacter pylori.

Secondary Outcome Measures

Name	Time	Method
Reduce the cost of treatment. Timepoint: 45 days. Method of measurement: Lower cost.;Less drug side effects. Timepoint: 45 days. Method of measurement: Patient clinical sign.